Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

The Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research program is a federal funding opportunity administered by the National Institutes of Health within the U.S. Department of Health and Human Services, specifically through the National Cancer Institute. This initiative is part of the broader Innovative Molecular Analysis Technologies Program, which focuses on advancing technological capabilities that support cancer research and clinical care. The program is designed to stimulate innovation at the earliest stages of technology development, particularly where proof-of-concept or pilot studies are needed to demonstrate feasibility and potential scientific impact. The primary objective of this funding opportunity is to support the development of novel technologies that can improve the analysis, targeting, handling, probing, or quality control of biospecimens used in cancer research. These technologies are expected to contribute to advancements in cancer biology, early detection, screening, diagnosis, treatment, epidemiology, and cancer control. Special emphasis is placed on projects that demonstrate high technical innovation and the potential to accelerate research progress or address cancer health disparities. While technologies may have broader applicability, proposals must clearly focus on cancer-related use cases within the scope of the application. Funding under this program supports early-stage development efforts, meaning that applicants are expected to propose pilot or feasibility studies rather than fully developed technologies or clinical trials. Clinical trials are explicitly not allowed under this funding mechanism. The award structure provides relatively modest funding amounts intended to validate innovative concepts before larger-scale investment. Allowable uses of funds include research activities necessary to design, test, and refine proposed technologies, but applicants must ensure alignment with NIH funding policies and restrictions. Eligibility for this opportunity is broad and inclusive, covering a wide range of organizational types. Eligible applicants include state and local governments, nonprofit organizations with or without 501(c)(3) status, institutions of higher education (both public and private), small businesses, for-profit organizations, tribal governments and organizations, public housing authorities, and other entities including foreign institutions. Federal agencies and regional organizations may also be eligible. This wide eligibility scope reflects the NIH’s intent to encourage diverse participation across sectors and geographic regions. The application process is expected to follow standard NIH submission procedures through Grants.gov, although specific submission instructions are not detailed in the forecast notice. Applicants should prepare a comprehensive proposal outlining the technical innovation, research plan, feasibility approach, and anticipated impact of the proposed technology. Evaluation criteria will likely emphasize scientific merit, innovation, feasibility, and potential to advance cancer research, consistent with NIH review standards. Contact for programmatic questions is provided, including a named program officer with both email and phone contact information. The timeline for this opportunity indicates that it is currently in a forecasted stage, with an estimated application due date of April 10, 2026, and an estimated award date of December 1, 2026. The anticipated project start date aligns with the award date. The opportunity is not described as recurring, and no pre-application requirements such as letters of intent are specified. As a forecasted opportunity, applicants are encouraged to monitor updates and prepare in advance for the official release and submission window.